Newer insulins in type 2 diabetes

BMJ (Online)

Volumn 345, Issue 7875, 2012, Pages

  Gale, Edwin A M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA;

ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CHOICE; DRUG COST; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; INSULIN, SHORT-ACTING;

EID: 84866612195     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4611     Document Type: Article

References (20)

1. Holleman F, Gale EAM. Nice insulins, pity about the evidence. Diabetologia 2007;50:1783-90.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
3. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010;53:2079-85.
4. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;6:CD008143.
5. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care. Royal College of Physicians, 2008.
6. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009;180:385-97.
7. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1-248.
8. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD005613.
9. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short-acting insulin analogues versus human insulin for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;2:CD003287.
10. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 2010;53:1743-53.
11. Sommerfeld MR, M̈ller G, Tschank G, Seipke G, Habermann P, et al. In vitro metabolic and mitogenic signalling of insulin glargine and its metabolites. PLoS One 2010;5(3):e9540.
12. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. New Engl J Med 2012;367:319-28.
13. NHS Information Centre for Health and Social Care. Prescribing for diabetes in England 2005/06 to 2010/11. 2011. www.ic.nhs.uk/statistics-and-data- collections/primary-care/prescriptions/prescribing-for-diabetes-in-england-2005- 06-to-2010-11.
14. Holden SE, Poole CD, Morgan CL, Currie CJ. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulins. BMJ Open 2011;1(2):e000258.
15. Cameron CG, Bennett HA. Cost effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009;180:400-7.
16. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47.
17. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7.
18. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;7:CD006383.
19. Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009;52:1990-2000.
20. Donnelly LA, Morris AD, Evans JM; DARTS/MEMO Collaboration. Adherence to insulin and its association with glucose control in patients with type 2 diabetes. QJM 2007;100:345-50.